Alzheimer’s Disease

Overview
Analytes
References

Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear after age 60. Estimates vary, but experts suggest that as many as 5.1 million Americans may have Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia among older people.

MSD provides solutions to support and simplify your Alzheimer’s disease research needs. We offer singleplex and multiplex assays to measure biomarkers such as Aβ38 peptide, APP, and Tau.

Title	Journal	Year
Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay Adam H. Dyer, Helena Dolphin, Antoinette O’Connor, Laura Morrison, Gavin Sedgwick, Conor Young, Emily Killeen, Conal Gallagher, Aoife McFeely, Eimear Connolly, Naomi Davey, Paul Claffey, Paddy Doyle, Shane Lyons, Christine Gaffney, Ruth Ennis, Cathy McHale, Jasmine Joseph, Graham Knight, Emmet Kelly, Cliona O’Farrelly, Aoife Fallon, Sean O’Dowd, Nollaig M. Bourke & Sean P. Kennelly	Biomedcentral	2024
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome Lawren VandeVrede, Renaud La Joie, Elisabeth H Thijssen, Breton M Asken, Stephanie A Vento, Torie Tsuei, Suzanne L Baker, Yann Cobigo, Corrina Fonseca, Hilary W Heuer, Joel H Kramer, Peter A Ljubenkov, Gil D Rabinovici, Julio C Rojas, Howie J Rosen, Adam M Staffaroni, Brad F Boeve, Brad C Dickerson, Murray Grossman, Edward D Huey, David J Irwin, Irene Litvan, Alexander Y Pantelyat, Maria Carmela Tartaglia, Jeffrey L Dage, Adam L Boxer	JAMA Neurology	2023
Lecanemab in Early Alzheimer's Disease Christopher H van Dyck, Chad J Swanson, Paul Aisen, Randall J Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael Irizarry, Lynn D Kramer, Takeshi Iwatsubo	The New England Journal of Medicine	2023
Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment Pia Kivisäkk, Thadryan Sweeney, Becky C. Carlyle, Bianca A. Trombetta, Kathryn LaCasse, Leena El-Mufti, Idil Tuncali, Lori B. Chibnik, Sudeshna Das, Clemens R. Scherzer, Keith A. Johnson, Bradford C. Dickerson, Teresa Gomez-Isla, Deborah Blacker, Derek H. Oakley, Matthew P. Frosch, Bradley T. Hyman, Anahit Aghvanyan, Pradeepthi Bathala, Christopher Campbell, George Sigal, Martin Stengelin, Steven E. Arnold	Frontiers in Neurology	2023
A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene. Sitek EJ, Narożańska E, Pepłońska B, Filipek S, Barczak A, Styczyńska M, Mlynarczyk K, Brockhuis B, Portelius E, Religa D, Barcikowska M, Sławek J, Zekanowski C.	PLoS One	2013
View All

Quick Links

Browse Our Products

By Analytes

By Applications

Contact Information

Customer Service/Orders
1-240-314-2795

5:00 a.m. to 8:00 p.m.
US Eastern Time

Email

Scientific/Technical Support
1-240-314-2798

8:30 a.m. to 5:30 p.m.
US Eastern Time

Email

Instrument Support
1-301-947-2057

8:30 a.m. - 5:30 p.m.
US Eastern Time

Email

Company Headquarters
1-240-314-2600
1601 Research Blvd.
Rockville, Maryland 20850-3173
USA

Please Sign In

User name

Password

Applications

Alzheimer’s Disease

Human

Mouse

Rat

Non-human primate

Quick Links

Browse Our Products

Contact Information

Products

Services

Orders & Support

Key Topics